Efficacy of T-2307, a novel arylamidine, against ocular complications of disseminated candidiasis in mice | Zendy

Masahiro Abe | Zendy; Shigeki Nakamura | Zendy; Yuki Kinjo | Zendy; Yuka Masuyama | Zendy; Junichi Mitsuyama | Zendy; Mitsuo Kaku | Zendy; Yoshitsugu Miyazaki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of T-2307, a novel arylamidine, against ocular complications of disseminated candidiasis in mice

Author(s) -

Masahiro Abe,

Shigeki Nakamura,

Yuki Kinjo,

Yuka Masuyama,

Junichi Mitsuyama,

Mitsuo Kaku,

Yoshitsugu Miyazaki

Publication year - 2019

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkz020

Subject(s) - candida albicans , fluconazole , amphotericin b , corpus albicans , medicine , microbiology and biotechnology , in vitro , mycosis , antifungal , immunology , pharmacology , biology , biochemistry

T-2307, a novel arylamidine, shows broad-spectrum activity against pathogenic fungi, including Candida albicans. Ocular candidiasis is one of the serious complications associated with Candida bloodstream infection and is known to be refractory to conventional antifungal agents. The aim of the present study was to clarify the effectiveness of T-2307 against ocular candidiasis using a mouse model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research